与全球申办者合作的广泛项目

OCT全面的CRO系列服务包括29个治疗领域中的300多项I-IV期临床试验。

欢迎致电

自2005年起,OCT团队一直在进行临床试验。我们积极主导欧洲、独联体国家和俄罗斯的项目,为客户提供从研究规划阶段到药物注册的支持。

十多年来,OCT已经参与了300多个全方位服务项目和个人临床开发服务。这些丰富的经验使我们具备评估潜在风险的能力,能够在项目规划的初始阶段就及时采取预防措施。


项目
患者

不同治疗领域的经验

分阶段经验

治疗体验中心

所有治疗领域
适应症
阶段
年份
试验类型
Polycystic Kidney Disease
III
2022
Interventional
COVID-19 (Vaccine)
III
2021
Interventional
Post-COVID-19 Pneumofibrosis
III
2021
Interventional
COVID-19 Vaccine (Partial Service)
III
2020
Interventional
Healthy Volunteers
Bioequivalence
2020
Interventional
Healthy Volunteers
Bioequivalence
2020
Interventional
Healthy Volunteers
Bioequivalence
2020
Interventional
Healthy Volunteers
Bioequivalence
2020
Interventional
Recurrent Vulvovaginal Candidiasis
III
2020
Interventional
Follicular Lymphoma
III
2020
Interventional
Acute Back Pain
III
2020
Interventional
Ulcerative Colitis
III
2020
Interventional
Nail Mycosis (Partial Service)
III
2020
Interventional
Atopic Dermatitis (Partial Service)
II
2020
Interventional
Healthy Volunteers
Bioequivalence
2020
Interventional
Ulcerative Colitis
II
2020
Interventional
Netherton Syndrome (Partial Service)
III
2020
Interventional
COVID-19 (Vaccine)
III
2020
Interventional
COVID-19 (Vaccine)
III
2020
Interventional
COVID-19 Vaccine (Partial Service)
II b/III
2020
Interventional
COVID-19 (Vaccine)
III
2020
Interventional
Healthy volunteers
Bioequivalence
2020
Interventional
Pelvic Inflammatory Disease
III
2020
Interventional
Nosocomial Pneumonia
III
2019
Interventional
Peritoneal Commissures
III
2019
Interventional
Healthy Volunteers
Bioequivalence
2019
Interventional
Acute Respiratory Viral Infection
III
2019
Interventional
Knee Pain
III
2019
Interventional
Back Pain
III
2019
Interventional
Gastritis
I
2019
Interventional
Chronic Discogenic Low Back Pain
II
2019
Interventional
Dyspepsia
III
2019
Interventional
Chron's Disease
III
2019
Interventional
Chronic Myeloid Leucosis (Partial Service)
II
2019
Interventional
Multiple Sclerosis
III
2019
Interventional
Breast Cancer
III
2019
Interventional
Musculo-Sceletal Injuries (Partial Service)
III
2019
Interventional
Chronic Myeloid Leukemia
III
2019
Interventional
Biliary Colic
III
2019
Interventional
Nutrition
N/A
2019
Non-interventional
Healthy Volunteers
Bioequivalence
2018
Interventional
Erectile Dysfunction
III
2018
Interventional
Glabellar Lines
III
2018
Interventional
Ulcerative Сolitis
III
2018
Interventional
Atherosclerosis
II
2018
Interventional
Healthy Volunteers
I
2018
Interventional
Craniocerebral Injury
III
2018
Interventional
Advanced Solid Tumor
I
2018
Interventional
Glaucoma
III
2018
Interventional
Venous Thrombosis
II
2018
Interventional
Acute Viral Respiratory Infections
III
2018
Interventional
Acute Hemorrhoids
III
2018
Interventional
Intensive Care
II
2017
Interventional
Influenza Vaccine
III
2017
Interventional
Rheumatoid Arthritis (Partial Service)
III
2017
Interventional
EGFR-Mutant NSCLC (Partial Service0
II
2017
Interventional
Ulcerative Colitis
I
2017
Interventional
Solid Tumors
I
2017
Interventional
Hematological Cancers (Partial Service)
I
2017
Interventional
Tuberculosis
I
2017
Interventional
Acute Diarrhea
III
2017
Interventional
Diabetic Polyneuropathy
II
2017
Interventional
Osteoarthrosis
IV (Post-marketing)
2017
Non-interventional
Colorectal Cancer
III
2017
Interventional
Non-Hodgkin’s Lymphoma
II
2017
Interventional
Atherosclerosis
III
2017
Interventional
Influenza
I
2017
Interventional
Female Sexual Arousal Disorder
III
2017
Interventional
Seborrheic dermatitis
III
2017
Interventional
Cerebrovascular Circulation Disorders (Partial Service)
N/A
2017
Interventional
Influenza Vaccine (Partial Service)
II
2016
Interventional
Acute Dental Pain
III
2016
Interventional
Rheumatoid Arthritis
III
2016
Interventional
Ulcerative Proctitis
II
2016
Interventional
Influenza Vaccine (Partial Service)
IV (Post-marketing)
2016
Non-interventional
Chronic Delta Hepatitis (Partial Service)
II
2016
Interventional
Tuberculosis (Partial Service)
II
2016
Interventional
Idiopathic Pulmonary Fibrosis (Partial Service)
II
2016
Interventional
Influenza Vaccine (Partial Service)
I
2016
Interventional
Cough on Acute Upper Respiratory Infection (Partial Service)
III
2016
Interventional
Tuberculosis
II
2016
Interventional
Rheumatoid Arthritis
III
2016
Interventional
Unspecified Adult Solid Tumors (Partial Service)
I
2016
Interventional
Chronic Lymphocytic Leukemia
III
2016
Interventional
Breast Cancer
III
2016
Interventional
Healthy Volunteers
Bioequivalence
2016
Interventional
Acute Gout
II
2016
Interventional
Healthy Volunteers
Bioequivalence
2016
Interventional
Healthy Volunteers
Bioequivalence
2016
Interventional
Post Traumatic Inflamation of Soft Tissues (Partial Service)
III
2016
Interventional
Acute Non-Specific Lower Back Pain
III
2016
Interventional
Healthy Volunteers
I
2016
Interventional
Meniere’s Disease and/or Vestibular Vertigo (partial service)
III
2016
Interventional
Healthy volunteers
I
2016
Interventional
Healthy Volunteers
Bioequivalence
2015
Interventional
Healthy Volunteers
Bioequivalence
2015
Interventional
Anal Fissure
III
2015
Interventional
Cardiac Monitoring
III
2015
Interventional
Tuberculosis
I
2015
Interventional
Breast Cancer
III
2015
Interventional
Colorectal Cancer (Partial Service)
II
2015
Interventional
Rheumatoid Arthritis (Partial Service)
III
2015
Interventional
Healthy Volunteers (Partial Service)
I
2015
Interventional
Rheumatoid Arthritis
III
2015
Interventional
Breast Cancer
II
2015
Interventional
Chronic Myeloid Leukemia
I
2015
Interventional
Healthy Volunteers
I
2015
Interventional
HIV (Partial Service)
IV (Post-marketing)
2015
Non-interventional
Astenospermia
II
2015
Interventional
Breast Cancer
III
2015
Interventional
Locally Advanced Epithelial Ovarian Cancer, Primar
II
2015
Interventional
Mild Cognitive Impairment
III
2015
Interventional
Non-Small Cell Lung Cancer
III
2015
Interventional
Сhronic Myeloid Leukemia (Partial Service)
II
2015
Interventional
Healthy Volunteers
Bioequivalence
2015
Interventional
Healthy Volunteers
Bioequivalence
2015
Interventional
Healthy Volunteers
Bioequivalence
2015
Interventional
Psoriasis Vulgaris (Partial Service)
I
2015
Interventional
Renal Colics (Partial Service)
III
2015
Interventional
Chronic Blepharoconjunctivitis
III
2015
Interventional
Female Sexual Arousal Disorder
II
2015
Interventional
Heart Failure (Partial Service)
III
2014
Interventional
Vestibular Vertigo (Partial Service)
III
2014
Interventional
Infusion Therapy (Partial Service)
III
2014
Interventional
N/A
Pre-Clinical
2014
Interventional
Knee Replacement (Partial Service)
III
2014
Interventional
Community Aquired Pneumonia
III
2014
Interventional
Schizophrenia
II
2014
Interventional
Breast Cancer (Partial Service)
I
2014
Interventional
Chronic Obstructive Pulmonary Disease (Partial Service)
II
2014
Interventional
Complicated Urinary Tract Infections
III
2014
Non-interventional
Schizophrenia (Partial Service)
III
2014
Interventional
Solid Tumors (Partial Service)
I
2014
Interventional
Acute Myeloid Leucosis (Partial Service)
I
2014
Interventional
HIV (Partial Service)
II
2014
Interventional
Hypoxic Central Nervous System Injury (Partial Service)
III
2014
Interventional
Alzheimer Disease
IV (Post-marketing)
2014
Interventional
Parenteral Nutrition (Partial Service)
III
2014
Interventional
Corneal Injury (Partial Service)
I
2014
Interventional
Deep Vein Thrombosis (Partial Service)
III
2014
Interventional
Healthy Volunteers
I
2014
Interventional
Metastatic Colon Cancer (Partial Service)
III
2014
Interventional
B-Cell Lymphoma
III
2014
Interventional
Healthy volunteers
I
2014
Interventional
Diabetes Mellitus Type 2 (Partial Service)
IV (Post-marketing)
2013
Non-interventional
N/A (Partial Service)
Pre-Clinical
2013
Interventional
Healthy Volunteers
Bioequivalence
2013
Interventional
Healthy Volunteers
Bioequivalence
2013
Interventional
N/A
Pre-Clinical
2013
Interventional
Breast Cancer
IV (Post-marketing)
2013
Non-interventional
Chronic Obstructive Pulmonary Disease (Partial Service)
IV (Post-marketing)
2013
Non-interventional
Chronic Prostatitis (Partial Service)
IV (Post-marketing)
2013
Non-interventional
Diabetes Mellitus Type 2
I
2013
Interventional
Essential Hypertension
III
2013
Interventional
LV Insufficiency
IV (Post-marketing)
2013
Interventional
Metastatic Cancer
I
2013
Interventional
Non-small Cell Lung Cancer (Partial Service)
IV (Post-marketing)
2013
Non-interventional
Multiple Drug Resistant Tuberculosis
IV (Post-marketing)
2013
Interventional
Multiple Sclerosis (Partial Service)
III
2013
Interventional
Solid Tumors
I
2013
Interventional
Community Aquired Pneumonia
III
2013
Interventional
Ovarian Cancer (Partial Service)
I
2013
Interventional
Outpatient Pneumonia (Partial Service)
IV (Post-marketing)
2013
Non-interventional
Recurrent Upper Respiratory Tract Infections
III
2013
Interventional
Respiratory Tract Infection
IV (Post-marketing)
2013
Non-interventional
Rheumatoid Arthritis (Partial Service)
I
2013
Interventional
Rheumatoid Arthritis (Partial Service)
III
2013
Interventional
Endometrial Carcinoma (Partial Service)
II
2013
Interventional
Sore Throat
III
2013
Interventional
Arterial Hypertension
IV (Post-marketing)
2013
Non-interventional
Vaginitis (partial service)
IV (Post-marketing)
2013
Non-interventional
Dislipidemia
I
2013
Interventional
Diarrhea (Partial Service)
IV (Post-marketing)
2013
Non-interventional
N/A
Pre-Clinical
2013
Interventional
Parenteral Nutrition (Partial Service)
III
2013
Interventional
Ulcerative Proctitis
II
2013
Interventional
N/A
Pre-Clinical
2013
Interventional
Chronic Prostatitis (Partial Service)
IV (Post-marketing)
2013
Non-interventional
Acute Otitis (Partial Service)
IV (Post-marketing)
2013
Non-interventional
Mucoviscidosis
I
2013
Interventional
Chronic Hepatitis B
II
2012
Interventional
Multiple Sclerosis
IV (Post-marketing)
2012
Non-interventional
Alcohol Abuse
II
2012
Interventional
Anxiety Disorder
II
2012
Interventional
Healthy Volunteers
Bioequivalence
2012
Interventional
Healthy Volunteers
Bioequivalence
2012
Interventional
Multiple Sclerosis
I
2012
Interventional
N/A
Pre-Clinical
2012
Interventional
Intensive Care
III
2012
Interventional
Acute Myeloid Leukemia
II
2012
Interventional
Atrial Fibrillation
IV (Post-marketing)
2012
Non-interventional
Healthy Volunteers
Bioequivalence
2012
Interventional
Healthy Volunteers
Bioequivalence
2012
Interventional
Breast Cancer
II
2012
Interventional
Chronic Kidney Disease
III
2012
Interventional
Coronary Artery Disease
III
2012
Interventional
Deep Vein Thrombosis
III
2012
Interventional
LV insufficiency
IV (Post-marketing)
2012
Interventional
Multiple Myeloma
III
2012
Interventional
Sore Throat
III
2012
Interventional
Thromboembolic Events
IV (Post-marketing)
2012
Non-interventional
HBeAg Negative Chronic Hepatitis B
II
2012
Interventional
Pregnancy Exposure
IV (Post-marketing)
2012
Non-interventional
Pain
III
2012
Interventional
Healthy volunteers
Bioequivalence
2012
Interventional
Ocular Inflammation Following Cataract Surgery
III
2012
Interventional
Asthma
III
2012
Interventional
Sore Throat
III
2012
Interventional
Healthy Volunteers
Bioequivalence
2011
Interventional
Infant Colic
II
2011
Interventional
Metastatic Breast Cancer
II
2011
Interventional
Asthma (Partial Service)
III
2011
Interventional
Back Pain
III
2011
Interventional
Healthy Volunteers
Bioequivalence
2011
Interventional
Biliary Colic (Partial Service)
III
2011
Interventional
Bladder Cancer (Partial Service)
II
2011
Interventional
Breast Cancer
II
2011
Interventional
Central Catheter's Maintanance (Partial Service)
III
2011
Interventional
Gout
III
2011
Interventional
Gynecology
III
2011
Interventional
Isolated Systolic Hypertension
III
2011
Interventional
Locally Advanced Pancreatic Cancer
II
2011
Interventional
Multiple Myeloma
III
2011
Interventional
N/A
Pre-Clinical
2011
Interventional
Rheumatoid Arthritis
IV (Post-marketing)
2011
Interventional
Solid Tumors
I
2011
Interventional
Stable Angina
IV (Post-marketing)
2011
Interventional
Essential Arterial Hypertension
III
2011
Interventional
Parenteral Nutrition
III
2011
Interventional
Ischemic Foot Ulcers
III
2011
Interventional
Sore Throat
II
2010
Interventional
Colorectal Cancer (Partial Service)
III
2010
Interventional
Colorectal Cancer (Partial Service)
II
2010
Interventional
Endometrial Carcinoma
II
2010
Interventional
Intestinal Colics
IV (Post-marketing)
2010
Non-interventional
Major Orthopedic Surgery (Pain Model)
III
2010
Interventional
Rhinnitis
IV (Post-marketing)
2010
Non-interventional
Solid Tumors
II
2010
Interventional
Colorectal Anastomosis
I
2010
Interventional
Colorectal Cancer
III
2010
Interventional
Head and Neck Cancer (Partial Service)
III
2010
Interventional
Mastocytosis
II
2010
Interventional
Acute Bronchitis
IV (Post-marketing)
2010
Non-interventional
Liver disorder
IV (Post-marketing)
2010
Non-interventional
Breast Cancer
II
2010
Interventional
Rheumatoid Arthritis (Partial Service)
II
2009
Interventional
Breast Cancer
III
2009
Interventional
Diabetes Mellitus
II
2009
Interventional
Erectile Dysfunction
III
2009
Interventional
Hypothyreosis
IV (Post-marketing)
2009
Non-interventional
Breast Cancer
II
2009
Interventional
Pulmonology/Pediatrics, Bronchitis, Pneumonia, AS
IV (Post-marketing)
2009
Non-interventional
Eradication of H. pylori
II
2009
Interventional
Hepatic cirrhosis
III
2009
Interventional
Pain
II
2008
Interventional
Crohn's Disease
II
2008
Interventional
Diabetes Mellitus
II
2008
Interventional
Brain Vessel Aneurism Rupture
III
2008
Interventional
Ovarian Cancer
III
2008
Interventional
Prostate Cancer (Partial Service)
II
2008
Interventional
Solid Tumors
I
2008
Interventional
Age-related Macular Degeneration
I
2008
Interventional
Rheumatoid Arthritis (Partial Service)
II
2008
Interventional
Acute Myeloid Leukosis
II
2007
Interventional
Acute Myocardial Infarction
IV (Post-marketing)
2007
Interventional
Healthy Volunteers
Bioequivalence
2007
Interventional
Breast Cancer
II
2007
Interventional
Breast Cancer
II
2007
Interventional
Breast Cancer, Neutropenia
III
2007
Interventional
Hepatic Metastases
II
2007
Interventional
Irritable Bowel Syndrome
III
2007
Interventional
Pain
II
2007
Interventional
Prostate Cancer
II
2007
Interventional
Acne
II
2006
Interventional
Nutrition
III
2006
Interventional
Acute Heart Failure
III
2006
Interventional
Immunotherapy in Renal Cell Carcinoma
III
2005
Interventional
T-cell Leukemia
II
2005
Interventional
显示更多
欢迎致电

Thank you for your request!
Our team will respond to you within 24 hours.